Rare and Common Variants in GALNT3 May Affect Bone Mass Independently of Phosphate Metabolism

Anabolic treatment options for osteoporosis remain limited. One approach to discovering novel anabolic drug targets is to identify genetic causes of extreme high bone mass (HBM). We investigated a pedigree with unexplained HBM within the UK HBM study, a national cohort of probands with HBM and their relatives. Whole exome sequencing (WES) in a family with HBM identified a rare heterozygous missense variant (NM_004482.4:c.1657C > T, p.Arg553Trp) in GALNT3, segregating appropriately. Interrogation of data from the UK HBM study and the Anglo‐Australasian Osteoporosis Genetics Consortium (AOGC) revealed an unrelated individual with HBM with another rare heterozygous variant (NM_004482.4:c.831 T > A, p.Asp277Glu) within the same gene. In silico protein modeling predicted that p.Arg553Trp would disrupt salt‐bridge interactions, causing instability of GALNT3, and that p.Asp277Glu would disrupt manganese binding and consequently GALNT3 catalytic function. Bi‐allelic loss‐of‐function GALNT3 mutations alter FGF23 metabolism, resulting in hyperphosphatemia and causing familial tumoral calcinosis (FTC). However, bone mineral density (BMD) in FTC cases, when reported, has been either normal or low. Common variants in the GALNT3 locus show genome‐wide significant associations with lumbar, femoral neck, and total body BMD. However, no significant associations with BMD are observed at loci coding for FGF23, its receptor FGFR1, or coreceptor klotho. Mendelian randomization analysis, using expression quantitative trait loci (eQTL) data from primary human osteoblasts and genome‐wide association studies data from UK Biobank, suggested increased expression of GALNT3 reduces total body, lumbar spine, and femoral neck BMD but has no effect on phosphate concentrations. In conclusion, rare heterozygous loss‐of‐function variants in GALNT3 may cause HBM without altering phosphate concentration. These findings suggest that GALNT3 may affect BMD through pathways other than FGF23 regulation, the identification of which may yield novel anabolic drug targets for osteoporosis. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

[1]  Kentaro Kato,et al.  Polypeptide N-acetylgalactosaminyltransferase-Associated Phenotypes in Mammals , 2021, Molecules.

[2]  T. Strom,et al.  A novel homozygous variant in exon 10 of the GALNT3 gene causing hyperphosphatemic familial tumoral calcinosis in a family from North India. , 2021, Intractable & rare diseases research.

[3]  E. McCloskey,et al.  Increased development of radiographic hip osteoarthritis in individuals with high bone mass: a prospective cohort study , 2020, Arthritis Research & Therapy.

[4]  Elizabeth G. Atkinson,et al.  The impact of non-additive genetic associations on age-related complex diseases , 2020, Nature Communications.

[5]  Ryan W. Kim,et al.  Rare Non-coding Variation Identified by Large Scale Whole Genome Sequencing Reveals Unexplained Heritability of Type 2 Diabetes: Trans-Omics for Precision Medicine (TOPMed) Program , 2020, medRxiv.

[6]  E. Duncan,et al.  The Genetic Architecture of High Bone Mass , 2020, Frontiers in Endocrinology.

[7]  Fernando Rivadeneira,et al.  The Musculoskeletal Knowledge Portal: Making Omics Data Useful to the Broader Scientific Community , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  B. Vandermeer,et al.  Persistence and adherence to parenteral osteoporosis therapies: a systematic review , 2020, Osteoporosis International.

[9]  C. Gregson,et al.  Individuals with High Bone Mass have increased progression of radiographic and clinical features of knee osteoarthritis. , 2020, Osteoarthritis and cartilage.

[10]  I. Heydari,et al.  Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene , 2020, Journal of Endocrinological Investigation.

[11]  S. Fukumoto,et al.  Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23 , 2020, Calcified Tissue International.

[12]  Kentaro Kato,et al.  Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3 , 2020, Nature Chemical Biology.

[13]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[14]  Shirly Pinto,et al.  Hyperphosphataemic familial tumoral calcinosis: case report of a rare and challenging disease , 2020, Scandinavian journal of rheumatology.

[15]  M. Brown,et al.  A Rare Mutation in SMAD9 Associated With High Bone Mass Identifies the SMAD‐Dependent BMP Signaling Pathway as a Potential Anabolic Target for Osteoporosis , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  O. Andreassen,et al.  A global overview of pleiotropy and genetic architecture in complex traits , 2019, Nature Genetics.

[17]  Cassandra N. Spracklen,et al.  Identification of type 2 diabetes loci in 433,540 East Asian individuals , 2019, bioRxiv.

[18]  M. McCarthy,et al.  Genome-wide association study of type 2 diabetes in Africa , 2019, Diabetologia.

[19]  C. Roux,et al.  Hyperphosphatemic Familial Tumoral Calcinosis With Galnt3 Mutation: Transient Response to Anti‐Interleukin‐1 Treatments , 2019, JBMR plus.

[20]  Jacob F. Degner,et al.  Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval , 2019, bioRxiv.

[21]  M. Yılmaz,et al.  Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in GALNT3 Gene: Experience from Southern Turkey , 2018, Journal of clinical research in pediatric endocrinology.

[22]  David M. Evans,et al.  An atlas of genetic influences on osteoporosis in humans and mice , 2018, Nature Genetics.

[23]  David M. Evans,et al.  Genome-wide association study of extreme high bone mass: Contribution of common genetic variation to extreme BMD phenotypes and potential novel BMD-associated genes , 2018, Bone.

[24]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[25]  M. Kanai,et al.  Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases , 2018, Nature Genetics.

[26]  David M. Evans,et al.  Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects. , 2018, American journal of human genetics.

[27]  Blair H. Smith,et al.  Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) , 2017, International journal of epidemiology.

[28]  Taesung Park,et al.  Sequence data and association statistics from 12,940 type 2 diabetes cases and controls , 2017, Scientific Data.

[29]  Jacqueline K. White,et al.  Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis , 2017, Nature Genetics.

[30]  Steve Epstein,et al.  Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease , 2017, Nature Genetics.

[31]  Rachel G Liao,et al.  A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes , 2017, Diabetes.

[32]  P. Visscher,et al.  Causal associations between risk factors and common diseases inferred from GWAS summary data , 2017, bioRxiv.

[33]  Giovanni Malerba,et al.  Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes , 2017, Nature Genetics.

[34]  Tanya M. Teslovich,et al.  An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans , 2017, Diabetes.

[35]  Andrea Gazzo,et al.  PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update , 2017, Nucleic Acids Res..

[36]  Karen L. Mohlke,et al.  The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases , 2017, Journal of Lipid Research.

[37]  N. Sheehan,et al.  A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomization , 2017, Statistics in medicine.

[38]  Dylan S. Small,et al.  A review of instrumental variable estimators for Mendelian randomization , 2015, Statistical methods in medical research.

[39]  Li-hao Sun,et al.  Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis , 2016, Bone Research.

[40]  K. White,et al.  Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis‐Hyperphosphatemia Syndrome , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  Stephen C. J. Parker,et al.  The genetic architecture of type 2 diabetes , 2016, Nature.

[42]  M. Brown,et al.  Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  Christian Gieger,et al.  Genetic fine-mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci , 2016 .

[44]  Beth Wilmot,et al.  Edinburgh Explorer Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture , 2022 .

[45]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .

[46]  A. Franchi,et al.  Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization , 2015, Calcified Tissue International.

[47]  J. de Nanassy,et al.  GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis , 2015, Scandinavian journal of rheumatology.

[48]  S. Johansson,et al.  Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature , 2014, BMC Genetics.

[49]  T. Spector,et al.  Prevalence of radiographic hip osteoarthritis is increased in high bone mass , 2014, Osteoarthritis and cartilage.

[50]  Nicholette D. Palmer,et al.  Meta-Analysis of Genome-Wide Association Studies in African Americans Provides Insights into the Genetic Architecture of Type 2 Diabetes , 2014, PLoS genetics.

[51]  K. White,et al.  Hyperphosphatemic familial tumoral calcinosis: Response to acetazolamide and postulated mechanisms , 2014, American journal of medical genetics. Part A.

[52]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[53]  Tanya M. Teslovich,et al.  Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility , 2014, Nature Genetics.

[54]  Cesar Libanati,et al.  Romosozumab in postmenopausal women with low bone mineral density , 2014, The New England journal of medicine.

[55]  Tanya M. Teslovich,et al.  Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico , 2013, Nature.

[56]  Y. Teo,et al.  A Study Assessing the Association of Glycated Hemoglobin A1C (HbA1C) Associated Variants with HbA1C, Chronic Kidney Disease and Diabetic Retinopathy in Populations of Asian Ancestry , 2013, PloS one.

[57]  M. Brown,et al.  Short-rib polydactyly and Jeune syndromes are caused by mutations in WDR60. , 2013, American journal of human genetics.

[58]  E. McCloskey,et al.  Analysis of Body Composition in Individuals With High Bone Mass Reveals a Marked Increase in Fat Mass in Women But Not Men , 2013, The Journal of clinical endocrinology and metabolism.

[59]  Steve D. M. Brown,et al.  A Mouse with an N-Ethyl-N-Nitrosourea (ENU) Induced Trp589Arg Galnt3 Mutation Represents a Model for Hyperphosphataemic Familial Tumoural Calcinosis , 2012, PloS one.

[60]  Tanya M. Teslovich,et al.  Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes , 2012, Nature Genetics.

[61]  Jing Hu,et al.  SIFT web server: predicting effects of amino acid substitutions on proteins , 2012, Nucleic Acids Res..

[62]  Daniel L. Koller,et al.  Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture , 2012, Nature Genetics.

[63]  M. Brown,et al.  Multicentric carpotarsal osteolysis is caused by mutations clustering in the amino-terminal transcriptional activation domain of MAFB. , 2012, American journal of human genetics.

[64]  R. Eastell,et al.  Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high‐bone‐mass phenotype due to a mutation in Lrp5 , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[65]  Sabine Geisse,et al.  Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function* , 2011, The Journal of Biological Chemistry.

[66]  E. McCloskey,et al.  ‘Sink or swim’: an evaluation of the clinical characteristics of individuals with high bone mass , 2011, Osteoporosis International.

[67]  E. Sprecher,et al.  Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis , 2011, Journal of Bone and Mineral Metabolism.

[68]  Leah R. Padgett,et al.  Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations , 2010, American journal of medical genetics. Part A.

[69]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[70]  Daniel Sinnett,et al.  Population genomics in a disease targeted primary cell model. , 2009, Genome research.

[71]  E. Evans,et al.  Familial tumoral calcinosis: a forty-year follow-up on one family. , 2009, The Journal of bone and joint surgery. American volume.

[72]  M. Indelman,et al.  Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemia syndrome , 2009, Acta orthopaedica.

[73]  A. Flanagan,et al.  Familial tumoral calcinosis and hyperostosis–hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3 , 2009, Skeletal Radiology.

[74]  E. Farrow,et al.  A case of familial tumoral calcinosis/hyperostosis–hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features , 2009, Osteoporosis International.

[75]  S. Lepreux,et al.  Tumoral calcinosis due to GALNT3 C.516-2A >T mutation in a black African family. , 2008, Genetic counseling.

[76]  K. White,et al.  Two novel GALNT3 mutations in familial tumoral calcinosis , 2007, American journal of medical genetics. Part A.

[77]  M. Econs,et al.  Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. , 2007, The Journal of clinical endocrinology and metabolism.

[78]  J. Devogelaer,et al.  Novel LRP5 Missense Mutation in a Patient With a High Bone Mass Phenotype Results in Decreased DKK1‐Mediated Inhibition of Wnt Signaling* , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[79]  P. Beck‐Peccoz,et al.  Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis , 2007, Journal of Human Genetics.

[80]  A. Tosteson,et al.  Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025 , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[81]  Y. Frishberg,et al.  Hyperostosis–Hyperphosphatemia Syndrome: A Congenital Disorder of O‐Glycosylation Associated With Augmented Processing of Fibroblast Growth Factor 23 , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[82]  M. Econs,et al.  Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. , 2006, The Journal of clinical endocrinology and metabolism.

[83]  I. Dianzani,et al.  Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family , 2006, Journal of Clinical Pathology.

[84]  M. Indelman,et al.  Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred , 2006, Journal of Human Genetics.

[85]  M. Econs,et al.  A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. , 2005, The Journal of clinical endocrinology and metabolism.

[86]  D. Behar,et al.  Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders , 2005, Journal of Molecular Medicine.

[87]  S. Mumm,et al.  High-bone-mass disease and LRP5. , 2004, The New England journal of medicine.

[88]  D. Behar,et al.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis , 2004, Nature Genetics.

[89]  P. Beighton,et al.  The natural history of sclerosteosis , 2003, Clinical genetics.

[90]  L. Hofbauer,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[91]  D. Galas,et al.  A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. , 2002, American journal of medical genetics.

[92]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[93]  K. Lindpaintner,et al.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease , 2002, Journal of medical genetics.

[94]  D. Galas,et al.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. , 2001, American journal of human genetics.

[95]  C. Cooper,et al.  Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. , 1997, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.